179 related articles for article (PubMed ID: 37169953)
21. Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model.
Thangaraj JL; Ahn SY; Jung SH; Vo MC; Chu TH; Thi Phan MT; Kwon M; Lee KH; Kim M; Song GY; Yang DH; Ahn JS; Kim HJ; Cho D; Lee JJ
Cell Mol Immunol; 2021 Jul; 18(7):1652-1661. PubMed ID: 33980993
[TBL] [Abstract][Full Text] [Related]
22. Combination doxorubicin and interferon-α therapy stimulates immunogenicity of murine pancreatic cancer Panc02 cells via up-regulation of NKG2D ligands and MHC class I.
Wang WJ; Qin SH; Zhang JW; Jiang YY; Zhang JN; Zhao L
Asian Pac J Cancer Prev; 2014; 15(22):9667-72. PubMed ID: 25520086
[TBL] [Abstract][Full Text] [Related]
23. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
Bellone G; Novarino A; Vizio B; Brondino G; Addeo A; Prati A; Giacobino A; Campra D; Fronda GR; Ciuffreda L
Int J Oncol; 2009 Jun; 34(6):1701-15. PubMed ID: 19424589
[TBL] [Abstract][Full Text] [Related]
24. Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy.
Chang SK; Hou J; Chen GG; Yu DD; Wu HQ; Xie YS; Hu LN; Gao L; Xiao WQ; Kong YY; Tao Y; Shi JM
Neoplasma; 2018 Sep; 65(5):720-729. PubMed ID: 29940772
[TBL] [Abstract][Full Text] [Related]
25. Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression.
Xu X; Rao GS; Groh V; Spies T; Gattuso P; Kaufman HL; Plate J; Prinz RA
BMC Cancer; 2011 May; 11():194. PubMed ID: 21605422
[TBL] [Abstract][Full Text] [Related]
26. Identification and characterization of a tumor infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and prostate cancer cell lines.
Frankel TL; Burns W; Riley J; Morgan RA; Davis JL; Hanada K; Quezado M; Rosenberg SA; Royal RE
Cancer Immunol Immunother; 2010 Dec; 59(12):1757-69. PubMed ID: 20734041
[TBL] [Abstract][Full Text] [Related]
27. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.
Liu J; Ma J; Wu Z; Li W; Zhang D; Han L; Wang F; Reindl KM; Wu E; Ma Q
BMC Cancer; 2014 Sep; 14():686. PubMed ID: 25240403
[TBL] [Abstract][Full Text] [Related]
28. NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors.
Morisaki T; Hirano T; Koya N; Kiyota A; Tanaka H; Umebayashi M; Onishi H; Katano M
Anticancer Res; 2014 Aug; 34(8):4529-38. PubMed ID: 25075096
[TBL] [Abstract][Full Text] [Related]
29. Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer.
Chung MJ; Park JY; Bang S; Park SW; Song SY
Cancer Immunol Immunother; 2014 Sep; 63(9):939-46. PubMed ID: 24916038
[TBL] [Abstract][Full Text] [Related]
30. IL-18/IL-15/IL-12 synergy induces elevated and prolonged IFN-γ production by ex vivo expanded NK cells which is not due to enhanced STAT4 activation.
Lusty E; Poznanski SM; Kwofie K; Mandur TS; Lee DA; Richards CD; Ashkar AA
Mol Immunol; 2017 Aug; 88():138-147. PubMed ID: 28644973
[TBL] [Abstract][Full Text] [Related]
31. Robo1-specific CAR-NK Immunotherapy Enhances Efficacy of
Xia N; Haopeng P; Gong JU; Lu J; Chen Z; Zheng Y; Wang Z; Sun YU; Yang Z; Hoffman RM; Liu F
Anticancer Res; 2019 Nov; 39(11):5919-5925. PubMed ID: 31704816
[TBL] [Abstract][Full Text] [Related]
32. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
33. Non-Coated Rituximab Induces Highly Cytotoxic Natural Killer Cells From Peripheral Blood Mononuclear Cells
Niu C; Chen Y; Li M; Zhu S; Zhou L; Xu D; Li Z; Xu J; Li W; Wang Y; Cui J
Front Immunol; 2021; 12():658562. PubMed ID: 34113342
[TBL] [Abstract][Full Text] [Related]
34. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
35. Real-Time Tracking of
Uong TNT; Lee KH; Ahn SJ; Kim KW; Min JJ; Hyun H; Yoon MS
Front Immunol; 2018; 9():825. PubMed ID: 29770131
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-21 increases direct cytotoxicity and IFN-γ production of ex vivo expanded NK cells towards breast cancer cells.
Park YK; Shin DJ; Cho D; Kim SK; Lee JJ; Shin MG; Ryang DW; Lee JS; Park MH; Yoon JH; Jegal YJ
Anticancer Res; 2012 Mar; 32(3):839-46. PubMed ID: 22399602
[TBL] [Abstract][Full Text] [Related]
37. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
38. Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells.
Deng X; Terunuma H; Nieda M; Xiao W; Nicol A
Int Immunopharmacol; 2012 Dec; 14(4):593-605. PubMed ID: 23063974
[TBL] [Abstract][Full Text] [Related]
39. Autologous natural killer cell therapy for human recurrent malignant glioma.
Ishikawa E; Tsuboi K; Saijo K; Harada H; Takano S; Nose T; Ohno T
Anticancer Res; 2004; 24(3b):1861-71. PubMed ID: 15274367
[TBL] [Abstract][Full Text] [Related]
40. Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy.
Cai H; Wang R; Guo X; Song M; Yan F; Ji B; Liu Y
Mol Pharm; 2021 Jul; 18(7):2495-2506. PubMed ID: 34078087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
